12
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      HIV testing history and access to treatment among migrants living with HIV in Europe

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Migrants are overrepresented in the European HIV epidemic. We aimed to understand the barriers and facilitators to HIV testing and current treatment and healthcare needs of migrants living with HIV in Europe.

          Methods

          A cross‐sectional study was conducted in 57 HIV clinics in nine countries (Belgium, Germany, Greece, Italy, The Netherlands, Portugal, Spain, Switzerland and United Kingdom), July 2013 to July 2015. HIV‐positive patients were eligible for inclusion if they were as follows: 18 years or older; foreign‐born residents and diagnosed within five years of recruitment. Questionnaires were completed electronically in one of 15 languages and linked to clinical records. Primary outcomes were access to primary care and previous negative HIV test. Data were analysed using random effects logistic regression. Outcomes of interest are presented for women, heterosexual men and gay/bisexual men.

          Results

          A total of 2093 respondents (658 women, 446 heterosexual men and 989 gay/bisexual men) were included. The prevalence of a previous negative HIV test was 46.7%, 43.4% and 82.0% for women, heterosexual and gay/bisexual men respectively. In multivariable analysis previous testing was positively associated with: receipt of post‐migration antenatal care among women, permanent residency among heterosexual men and identifying as gay rather than bisexual among gay/bisexual men. Access to primary care was found to be high (>83%) in all groups and was strongly associated with country of residence. Late diagnosis was common for women and heterosexual men (60.8% and 67.1%, respectively) despite utilization of health services prior to diagnosis. Across all groups almost three‐quarters of people on antiretrovirals had an HIV viral load <50 copies/mL.

          Conclusions

          Migrants access healthcare in Europe and while many migrants had previously tested for HIV, that they went on to test positive at a later date suggests that opportunities for HIV prevention are being missed. Expansion of testing beyond sexual health and antenatal settings is still required and testing opportunities should be linked with combination prevention measures such as access to PrEP and treatment as prevention.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

          Summary Background Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect. Methods PROUD is an open-label randomised trial done at 13 sexual health clinics in England. We enrolled HIV-negative gay and other men who have sex with men who had had anal intercourse without a condom in the previous 90 days. Participants were randomly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral period of 1 year. Randomisation was done via web-based access to a central computer-generated list with variable block sizes (stratified by clinical site). Follow-up was quarterly. The primary outcomes for the pilot phase were time to accrue 500 participants and retention; secondary outcomes included incident HIV infection during the deferral period, safety, adherence, and risk compensation. The trial is registered with ISRCTN (number ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). Findings We enrolled 544 participants (275 in the immediate group, 269 in the deferred group) between Nov 29, 2012, and April 30, 2014. Based on early evidence of effectiveness, the trial steering committee recommended on Oct 13, 2014, that all deferred participants be offered PrEP. Follow-up for HIV incidence was complete for 243 (94%) of 259 patient-years in the immediate group versus 222 (90%) of 245 patient-years in the deferred group. Three HIV infections occurred in the immediate group (1·2/100 person-years) versus 20 in the deferred group (9·0/100 person-years) despite 174 prescriptions of post-exposure prophylaxis in the deferred group (relative reduction 86%, 90% CI 64–96, p=0·0001; absolute difference 7·8/100 person-years, 90% CI 4·3–11·3). 13 men (90% CI 9–23) in a similar population would need access to 1 year of PrEP to avert one HIV infection. We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp. We detected no difference in the occurrence of sexually transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a suggestion of risk compensation among some PrEP recipients. Interpretation In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. There was no evidence of an increase in other sexually transmitted infections. Our findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection. Funding MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Migration and health in an increasingly diverse Europe.

            The share of migrants in European populations is substantial and growing, despite a slowdown in immigration after the global economic crisis. This paper describes key aspects of migration and health in Europe, including the scale of international migration, available data for migrant health, barriers to accessing health services, ways of improving health service provision to migrants, and migrant health policies that have been adopted across Europe. Improvement of migrant health and provision of access for migrants to appropriate health services is not without challenges, but knowledge about what steps need to be taken to achieve these aims is increasing. Copyright © 2013 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review.

              To identify the reasons why those offered a place on diabetes education programmes declined the opportunity.
                Bookmark

                Author and article information

                Contributors
                f.burns@ucl.ac.uk
                Journal
                J Int AIDS Soc
                J Int AIDS Soc
                10.1002/(ISSN)1758-2652
                JIA2
                Journal of the International AIDS Society
                John Wiley and Sons Inc. (Hoboken )
                1758-2652
                19 July 2018
                July 2018
                : 21
                : Suppl Suppl 4 , Population mobility: challenges for universal HIV testing and treatment, Guest Editors: Carol S Camlin, Susan Cassels, Janet Seeley ( doiID: 10.1111/jia2.2018.21.issue-S4 )
                : e25123
                Affiliations
                [ 1 ] Institute for Global Health University College London London United Kingdom
                [ 2 ] National Centre of Epidemiology Instituto de Salud Carlos III Madrid Spain
                [ 3 ] Department of Health and Socio‐medical Sciences University of Alcalá Alcalá de Henares Madrid
                [ 4 ] Department of Infectious Diseases CHU Saint‐Pierre Brussels Belgium
                [ 5 ] European AIDS Treatment Group
                [ 6 ] HIV Centre Frankfurt Germany
                [ 7 ] Department of Hygiene, Epidemiology& Medical Statistics Medical School National and Kapodistrian University of Athens Athens Greece
                [ 8 ] Academic Medical Centre University of Amsterdam Amsterdam the Netherlands
                [ 9 ] Public Health Service of Amsterdam the Netherlands
                [ 10 ] Faculty of Medicine University of Porto Porto Portugal
                [ 11 ] Lausanne University Hospital Lausanne Switzerland
                [ 12 ] Unit for Infectious Diseases and Assistance, Coordination and Territorial Integration for Migrants’ Emergency Civico‐ Benfratelli Hospital Palermo Italy
                [ 13 ] Royal Free London NHS Foundation Trust London England
                Author notes
                [*] [* ] Corresponding author: Fiona Burns, Institute for Global Health, University College London, 3rd Floor, Mortimer Market Centre, Mortimer Market, London, WC1E 6JB, UK. Tel: +44 203 108 2060. ( f.burns@ 123456ucl.ac.uk )
                [†]

                Both are senior co‐authors.

                [‡]

                Members of the aMASE Study Team are listed in the Appendix.

                Article
                JIA225123
                10.1002/jia2.25123
                6053481
                30027686
                505209dd-1219-4c8f-bd92-6ddfe93e1eec
                © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 14 December 2017
                : 16 May 2018
                Page count
                Figures: 0, Tables: 6, Pages: 14, Words: 13897
                Funding
                Funded by: European Union's Seventh Framework Programme for research, technological development and demonstration
                Award ID: 260,694
                Funded by: National Institute for Health Research
                Funded by: Gilead Sciences Europe Ltd.
                Funded by: NIHR Clinical Research Network
                Funded by: Foundation for AIDS Research and Prevention in Spain (FISPSE)
                Funded by: Consortium of Biomedical Research in Epidemiology and Public Health
                Funded by: Spanish HIV Research Network for Excellence
                Award ID: RD06/006
                Award ID: RD12/0017/0018
                Funded by: FIPSE (Fundación para la Prevención de SIDA en España)
                Funded by: Research and Development Fund, Public Health Service of Amsterdam
                Funded by: Swiss National Science Foundation
                Award ID: #148,522
                Funded by: SHCS Research Foundation
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                jia225123
                July 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.3 mode:remove_FC converted:19.07.2018

                Infectious disease & Microbiology
                hiv,migrants,hiv serodiagnosis,primary healthcare,health services accessibility

                Comments

                Comment on this article